Drug
Pa21
Pa21: highest development phase Phase 3, developed by Fresenius Kabi, Vifor Pharma. 2 trial records tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Fresenius Kabi, Vifor Pharma
Trials
| Drug | Phase | Indication |
|---|---|---|
| PA21 (Velphoro®) NCT02688764 | Phase 3 | Hyperphosphatemia |
| 1.25 g PA21 (250 mg iron) NCT00824460 | Phase 2 | Chronic Kidney Disease |
Latest
No recent events.
Follow Pa21 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.